|
|
|
|
||
Re: Ziopharm Oncology Names NCI’s Dr. Drew Deniger to Direct TCR-T Cell Therapy ProgramI forgot about BLUE's DARIC control [1] and other work [2] including CBL-B KO [3]. Adoptive cell transfer of CBL-B deficient CD8 T-cells were sufficient to eradicate already established tumours and the cells are less sensitive to suppression by Tregs [4,5]. This could bypass the requirement for exogenous IL-2 administration as well. Refs: |
return to message board, top of board |